form8k.htm

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
 
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported)
December 31, 2008
 
NovaBay Pharmaceuticals, Inc.
 
(Exact name of registrant as specified in its charter)
 
California
001-33678
68-0454536
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
 
5980 Horton Street, Suite 550, Emeryville, CA
 94608
(Address of principal executive offices)
 
(Zip Code)
Registrant’s telephone number, including area code
           (510) 899-8800
 
Not Applicable
 
(Former name or former address, if changed since last report)

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
£
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
£
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
£
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
£
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 

 
 
 


Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing;

NovaBay Pharmaceuticals, Inc.  has notified the Toronto Stock Exchange (TSX) of its intent to voluntarily remove its listing of common stock from the TSX in order to consolidate trading on the American Stock Exchange (AMEX) to achieve cost saving.

 
Item  9.01
Financial Statements and Exhibits
    (d)
Exhibits
 
Exhibit No.
Description
99.1
Press release of NovaBay Pharmaceuticals, Inc. dated December 31, 2008



 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

Dated:  December 31, 2008                                          NOVABAY PHARMACEUTICALS, INC.



By:   /s/ THOMAS PAULSON
Thomas J. Paulson
Chief Financial Officer and Treasurer